Research progress on the anti-Mycobacterium tuberculosis activity of sitafloxacin

doi:10.19982/j.issn.1000-6621.20250295

Abstract

Abstract:

The global tuberculosis epidemic remains severe, and China continues to be classified among the tuberculosis high-burden countries. Conventional fluoroquinolones are increasingly limited by cross-resistance and adverse-event profiles. Sitafloxacin, distinguished by its dual-target mechanism and good tissue penetration (The ratio of alveolar lining fluid concentration to plasma concentration is 54%), exhibits potent bactericidal activity against multidrug-resistant, rifampicin-resistant, pre-extensively drug-resistant, and extensively drug-resistant Mycobacterium tuberculosis strains. Comparative studies indicate that its early bactericidal activity surpasses that of levofloxacin and moxifloxacin, while its safety profile remains acceptable. Notably, the first documented case of pre-extensively drug-resistant tuberculosis has been successfully treated with sitafloxacin-based regimens. This review synthesizes recent advances in the use of sitafloxacin for tuberculosis therapy, aiming to provide an evidence-based reference for its clinical application.

Key words: Sitafloxacin, Tuberculosis, Antitubercular agents, Review literature as topic

CLC Number:

Wang Xueyu, Chu Naihui, Nie Wenjuan. Research progress on the anti-Mycobacterium tuberculosis activity of sitafloxacin[J]. Chinese Journal of Antituberculosis, 2026, 48(2): 299-303. doi: 10.19982/j.issn.1000-6621.20250295

References 35

[1]	中华医学会结核病学分会. 抗结核药物超说明书用法专家共识(2023年更新版). 中华结核和呼吸杂志, 2023, 46(11):1085-1102. doi:10.3760/cma.j.cn112147-20230809-00062.
[2]	Okumura R, Hirata T, Onodera Y, et al. Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase Ⅳ: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae. J Antimicrob Chemother, 2008, 62(1):98-104. doi:10.1093/jac/dkn136. URL pmid: 18390884
[3]	Chen TC, Lu PL, Lin CY, et al. Fluoroquinolones are associated with delayed treatment and resistance in tuberculosis: a systematic review and meta-analysis. Int J Infect Dis, 2011, 15(3):e211-e216. doi:10.1016/j.ijid.2010.11.008.
[4]	Keating GM. Sitafloxacin: in bacterial infections. Drugs, 2011, 71(6):731-744. doi:10.2165/11207380-000000000-00000. URL pmid: 21504249
[5]	孙倩倩, 张斌, 张珊珊, 等. 西他沙星体外抗菌活性试验研究. 中国医药生物技术, 2023, 18(4):339-343. doi:10.3969/j.issn.1673-713X.2023.04.008.
[6]	胡云建, 陈东科, 陶凤蓉, 等. 西他沙星的体外抗菌作用研究. 中国感染与化疗杂志, 2013, 13(1):52-58. doi:10.3969/j.issn.1009-7708.2013.01.011.
[7]	张婷婷, 乔红群, 丁亚军, 等. 富马酸西他沙星注射液体内抗菌作用研究. 中国抗生素杂志, 2018, 43(11):1426-1430. doi:10.3969/j.issn.1001-8689.2018.11.017.
[8]	柴芸, 刘明亮. 新氟喹诺酮类抗菌药西他沙星. 国外医药(抗生素分册), 2009, 30(6):264-270.
[9]	Nakashima M, Uematsu T, Kosuge K, et al. Pharmacokinetics and tolerance of DU-6859a, a new fluoroquinolone, after single and multiple oral doses in healthy volunteers. Antimicrob Agents Chemother, 1995, 39(1):170-174. doi:10.1128/AAC.39.1.170. URL pmid: 7695301
[10]	Tachibana M, Tanaka M, Mitsugi K, et al. Pharmacokinetics, tissue distribution, and excretion of sitafloxacin, a new fluoroquinolone antibiotic, in rats, dogs, and monkeys. Arzneimittelforschung, 2004, 54(12):898-905. doi:10.1055/s-0031-1297046.
[11]	Paiboonvong T, Nosoongnoen W, Sathirakul K, et al. Pharmacokinetics and Penetration of Sitafloxacin into Alveolar Epithelial Lining Fluid in Critically Ill Thai Patients with Pneumonia. Antimicrob Agents Chemother, 2019, 63(10):e00800-19. doi:10.1128/AAC.00800-19.
[12]	Zhanel GG, Ennis K, Vercaigne L, et al. A critical review of the fluoroquinolones: focus on respiratory infections. Drugs, 2002, 62(1):13-59. doi:10.2165/00003495-200262010-00002. URL pmid: 11790155
[13]	Mitsuyoshi Nakashima, Yukimichi Kawada. Pharmacokinetic profiles of sitafloxacin in patients with renal dysfunction. Japanese Journal of Chemotherapy, 2008,56:21-24. doi:10.11250/chemotherapy1995.56.Supplement1_21.
[14]	武晓捷, 范亚新, 张菁, 等. 口服西他沙星在中国健康受试者中的药动学及药动学/药效学研究. 中国感染与化疗杂志, 2018, 18(4): 352-359. doi:10.16718/j.1009-7708.2018.04.002.
[15]	Sun LN, Sun GX, Yang YQ, et al. Effects of ABCB1, UGT1A1, and UGT1A 9 Genetic Polymorphisms on the Pharmacokinetics of Sitafloxacin Granules in Healthy Subjects. Clin Pharmacol Drug Dev, 2021, 10(1):57-67. doi:10.1002/cpdd.848.
[16]	杨瑞芳, 蒙建州, 曹文利, 等. 西他沙星对分枝杆菌的体外抗菌活性研究. 中国新药杂志, 2022, 31(3):263-268. doi:10.3969/j.issn.1003-3734.2022.03.011.
[17]	Kong Y, Geng Z, Jiang G, et al. Comparison of the in vitro antibacterial activity of ofloxacin, levofloxacin, moxifloxacin, sitafloxacin, finafloxacin, and delafloxacin against Mycobacterium tuberculosis strains isolated in China. Heliyon, 2023, 9(11):e21216. doi:10.1016/j.heliyon.2023.e21216.
[18]	Leechawengwongs M, Prammananan T, Jaitrong S, et al. In Vitro Activity and MIC of Sitafloxacin against Multidrug-Resistant and Extensively Drug-Resistant Mycobacterium tuberculosis Isolated in Thailand. Antimicrob Agents Chemother, 2017, 62(1):e00825-17. doi:10.1128/AAC.00825-17.
[19]	Yi L, Aono A, Chikamatsu K, et al. In vitro activity of sitafloxacin against Mycobacterium tuberculosis with gyrA/B mutations isolated in Japan. J Med Microbiol, 2017, 66(6):770-776. doi:10.1099/jmm.0.000493.
[20]	Sun Q, Cheng K, Liao X, et al. New generation fluoroquino-lone sitafloxacin could potentially overcome the majority levofloxacin and moxifloxacin resistance in multidrug-resistant Mycobacterium tuberculosis. J Med Microbiol, 2024, 73(7). doi:10.1099/jmm.0.001825.
[21]	Sato K, Tomioka H, Sano C, et al. Comparative antimicrobial activities of gatifloxacin, sitafloxacin and levofloxacin against Mycobacterium tuberculosis replicating within Mono Mac 6 human macrophage and A-549 type Ⅱ alveolar cell lines. J Antimicrob Chemother, 2003, 52(2):199-203. doi:10.1093/jac/dkg343.
[22]	Saito H, Tomioka H, Sato K, et al. In vitro and in vivo antimycobacterial activities of a new quinolone, DU-6859a. Antimicrob Agents Chemother, 1994, 38(12):2877-2882. doi:10.1128/AAC.38.12.2877. URL pmid: 7695276
[23]	Nie L, Tong J, Wu G, et al. Early bactericidal activity of sitafloxacin against pulmonary tuberculosis. Microbiol Spectr, 2025, 13(1):e0164524. doi:10.1128/spectrum.01645-24.
[24]	Ball P. Adverse drug reactions: implications for the development of fluoroquinolones. J Antimicrob Chemother, 2003,51 Suppl 1:21-27. doi:10.1093/jac/dkg209.
[25]	Matsumoto T, Uchino K, Yamaguchi H, et al. Study on the safety and efficacy of sitafloxacin—results of the use-results survey. Jpn J Antibiot, 2011, 64(5):319-337.
[26]	Hori S, Uchino K, Matsumoto T, et al. Study on the safety and efficacy of sitafloxacin at a dose of 100 mg once a day—results of the use-results survey. Jpn J Antibiot, 2014, 67(3):175-191. doi: 10.1038/ja.2013.89
[27]	Lei Y, Luo P, Chen Y, et al. Pharmacokinetics and Safety Evaluation of a New Generic Sitafloxacin: A Phase I Bioequiva-lence Study in Healthy Chinese Participants. Clin Pharmacol Drug Dev, 2025, 14(8):592-597. doi:10.1002/cpdd.1519.
[28]	Chen CK, Cheng IL, Chen YH, et al. Efficacy and Safety of Sitafloxacin in the Treatment of Acute Bacterial Infection: A Meta-analysis of Randomized Controlled Trials. Antibiotics (Basel), 2020, 9(3):106. doi:10.3390/antibiotics9030106.
[29]	Shimoda K, Ikeda T, Okawara S, et al. Possible relationship between phototoxicity and photodegradation of sitafloxacin, a quinolone antibacterial agent, in the auricular skin of albino mice. Toxicol Sci, 2000, 56(2):290-296. doi:10.1093/toxsci/56.2.290. URL pmid: 10910986
[30]	Shimoda K, Okawara S, Kato M. Phototoxic retinal degeneration and toxicokinetics of sitafloxacin, a quinolone antibacterial agent, in mice. Arch Toxicol, 2001, 75(7):395-399. doi:10.1007/s002040100263. URL pmid: 11693179
[31]	Dawe RS, Ibbotson SH, Sanderson JB, et al. A randomized controlled trial (volunteer study) of sitafloxacin, enoxacin, levofloxacin and sparfloxacin phototoxicity. Br J Dermatol, 2003, 149(6): 1232-1241. doi:10.1111/j.1365-2133.2003.05582.x.
[32]	Chiba K, Sugiyama A, Hagiwara T, et al. In vivo experimental approach for the risk assessment of fluoroquinolone antibacterial agents-induced long QT syndrome. Eur J Pharmacol, 2004, 486(2):189-200. doi:10.1016/j.ejphar.2003.12.014.
[33]	Wakayama Y, Yoshimura S, Hanabusa K, et al. Torsades de pointes due to oral sitafloxacin. Acute Med Surg, 2023, 10(1):e910. doi:10.1002/ams2.910.
[34]	Hori S. Convulsant activity of sitafloxacin and its interactions with anti-inflammatory drugs in mice. J Infect Chemother, 2009, 15(4):266-268. doi:10.1007/s10156-009-0693-9. URL pmid: 19688249
[35]	张帆, 陈晓红, 初乃惠, 等. 含西他沙星的新的抗结核方案治疗准广泛耐药肺结核一例. 中国防痨杂志, 2024, 46(11):1410-1413. doi:10.19982/j.issn.1000-6621.20240262.